Nicole L Cohen1, Adrienne J Heinz1,2, Mark Ilgen3,4, Marcel O Bonn-Miller1,2,5,6. 1. National Center for PTSD, Veterans Affairs Palo Alto Health Care System, Menlo Park, California. 2. Center for Innovation to Implementation, Veterans Affairs Palo Alto Health Care System, Menlo Park, California. 3. Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan. 4. Department of Psychiatry, University of Michigan, Ann Arbor, Michigan. 5. Center of Excellence in Substance Abuse Treatment and Education, Philadelphia VA Medical Center, Philadelphia, Pennsylvania. 6. Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Abstract
OBJECTIVE: The purpose of this study was to examine whether individuals who used medical cannabis for chronic pain were at increased risk for cannabis use problems compared with individuals who used medical cannabis for other reasons (e.g., anxiety, insomnia, and muscle spasms). An additional aim was to determine whether individuals who used cannabis for chronic pain, as well as those who reported greater within-group pain levels, demonstrated a species preference (i.e., sativa, indica, hybrids) and the extent to which species preference was associated with cannabis use problems. METHOD: Participants were 163 medical cannabis users (77% male), recruited from a medical marijuana dispensary in California, who completed assessments of medical cannabis use motives, history, preferences (species type), and problems, as well as current pain level. RESULTS: Individuals who used cannabis to manage chronic pain experienced fewer cannabis use problems than those who did not use it for pain; among those who used it for pain, the average pain level in the past week was not associated with cannabis use problems. Furthermore, individuals who used cannabis for chronic pain were more likely to use indica over sativa. Preference for indica was associated with fewer cannabis use problems than preference for hybrid species. CONCLUSIONS: Individuals who use cannabis to manage chronic pain may be at a lower risk for cannabis use problems, relative to individuals who use it for other indications, potentially as a function of their species preference.
OBJECTIVE: The purpose of this study was to examine whether individuals who used medical cannabis for chronic pain were at increased risk for cannabis use problems compared with individuals who used medical cannabis for other reasons (e.g., anxiety, insomnia, and muscle spasms). An additional aim was to determine whether individuals who used cannabis for chronic pain, as well as those who reported greater within-group pain levels, demonstrated a species preference (i.e., sativa, indica, hybrids) and the extent to which species preference was associated with cannabis use problems. METHOD:Participants were 163 medical cannabis users (77% male), recruited from a medical marijuana dispensary in California, who completed assessments of medical cannabis use motives, history, preferences (species type), and problems, as well as current pain level. RESULTS: Individuals who used cannabis to manage chronic pain experienced fewer cannabis use problems than those who did not use it for pain; among those who used it for pain, the average pain level in the past week was not associated with cannabis use problems. Furthermore, individuals who used cannabis for chronic pain were more likely to use indica over sativa. Preference for indica was associated with fewer cannabis use problems than preference for hybrid species. CONCLUSIONS: Individuals who use cannabis to manage chronic pain may be at a lower risk for cannabis use problems, relative to individuals who use it for other indications, potentially as a function of their species preference.
Authors: Marcel O Bonn-Miller; Matthew Tyler Boden; Meggan M Bucossi; Kimberly A Babson Journal: Am J Drug Alcohol Abuse Date: 2013-11-08 Impact factor: 3.829
Authors: Christian D Schubart; Iris E C Sommer; Willemijn A van Gastel; Rogier L Goetgebuer; René S Kahn; Marco P M Boks Journal: Schizophr Res Date: 2011-05-17 Impact factor: 4.939
Authors: Zach Walsh; Robert Callaway; Lynne Belle-Isle; Rielle Capler; Robert Kay; Philippe Lucas; Susan Holtzman Journal: Int J Drug Policy Date: 2013-09-09
Authors: Amir Englund; Paul D Morrison; Judith Nottage; Dominic Hague; Fergus Kane; Stefania Bonaccorso; James M Stone; Avi Reichenberg; Rudolf Brenneisen; David Holt; Amanda Feilding; Lucy Walker; Robin M Murray; Shitij Kapur Journal: J Psychopharmacol Date: 2012-10-05 Impact factor: 4.153
Authors: Mark A Ilgen; Kipling Bohnert; Felicia Kleinberg; Mary Jannausch; Amy S B Bohnert; Maureen Walton; Frederic C Blow Journal: Drug Alcohol Depend Date: 2013-05-15 Impact factor: 4.492
Authors: Nancy A Haug; Claudia B Padula; James E Sottile; Ryan Vandrey; Adrienne J Heinz; Marcel O Bonn-Miller Journal: Addict Behav Date: 2017-03-09 Impact factor: 3.913
Authors: Bryan Hartzler; Beatriz H Carlini; Howard Newville; Heidi M Crane; Joseph J Eron; Elvin H Geng; W Christopher Mathews; Kenneth H Mayer; Richard D Moore; Michael J Mugavero; Sonia Napravnik; Benigno Rodriguez; Dennis M Donovan Journal: AIDS Care Date: 2016-12-23
Authors: Mary Beth Miller; Ryan W Carpenter; Lindsey K Freeman; Ashley F Curtis; Ali M Yurasek; Christina S McCrae Journal: J Clin Sleep Med Date: 2022-04-01 Impact factor: 4.062
Authors: Brienna N Meffert; Danielle M Morabito; Michelle K Mosich; Mallory J Loflin; James Sottile; Adrienne J Heinz Journal: Curr Drug Res Rev Date: 2019
Authors: Nancy A Haug; Dustin Kieschnick; James E Sottile; Kimberly A Babson; Ryan Vandrey; Marcel O Bonn-Miller Journal: Cannabis Cannabinoid Res Date: 2016-12-01